Category - Developments

Developments

Daxor awarded new U.S. DHA contract for blood volume analyzer upgrade

Daxor Corporation (NASDAQ:DXR) announced the receipt of a $550K matching-fund extension from the U.S. Defense Health Agency (DHA) for its Phase II SBIR contract. This additional funding will support the incorporation of...

July 24, 2024

Developments

BioResorative’s Chief Scientist named section editor of top-tier Journal of Translational Medicine

BioRestorative Therapies (NASDAQ:BTRX) announced that Francisco Silva, the company’s chief scientist and vice president of research and development, has been appointed section editor of the newly launched Regenerative...

July 23, 2024

Developments

Cytel unveiled as alliance partner with OneMedNet

Closely-held Cytel, a global leader in clinical trial design and software, announced today its strategic partnership with OneMedNet (NASDAQ:ONMD) to enhance data-driven healthcare solutions. The partnership will...

July 22, 2024

Developments

Anebulo announces NIDA grant for investigational treatment of acute cannabis-induced toxicities in children

Anebulo Pharmaceuticals (NASDAQ:ANEB) has been awarded the first tranche of a two-year, $1.9 million NIDA grant to develop intravenous selonabant for treating acute cannabis-induced toxicity, including CNS depression in...

July 22, 2024

Developments

Clearmind files additional U.S. patent application for MEAI to treat obesity

Clearmind Medicine (NASDAQ:CMND; FSE:CWYO) announced it has filed an additional patent application with the USPTO for the novel proprietary composition of its MEAI compound for treating metabolic syndrome and obesity...

July 16, 2024

Developments

Alto Neuroscience announces Phase 2b enrollment completion in MDD study

Alto Neuroscience (NYSE:ANRO) announced the completion of enrollment in its Phase 2b study evaluating ALTO-100 in 300 adults with major depressive disorder (MDD) across 34 U.S. sites. The randomized, double-blind...

July 16, 2024

Developments

CMS unveils proposed reimbursement for TULSA to treat prostate disease

Profound Medical (NASDAQ:PROF; TSX:PRN) announced that the U.S. Centers for Medicare and Medicaid Services has issued proposed rules establishing, for the first time, a Category 1 CPT code for the Transurethral...

July 12, 2024

Developments

Rainhouse spotlights CNN reveal on injection cartridge supply issues impacting weight-loss drug shortages

Rainhouse Manufacturing Canada, a well-established North American CNC machining and manufacturing company, emphasized a recent CNN interview with Dr. Sanjay Gupta, which uncovered the real cause of weight-loss drug...

July 12, 2024

Developments

Remembering Elias Vamvakas, a friend and mentor

For the first time since we began publishing in 2009, the BioTuesdays family is lost for words, almost. With devastating sadness, we learned today of Elias Vamvakas’ passing. A pioneering entrepreneur in the Canadian...

July 11, 2024

Developments

Exscientia launches AWS AI-powered platform to advance drug discovery

Exscientia plc (NASDAQ:EXAI) announced its use of Amazon Web Services (AWS) artificial intelligence and machine learning services to power its platform for end-to-end drug discovery and automation. Exscientia’s...

July 10, 2024

Category - Developments

Daxor awarded new U.S. DHA contract for blood volume analyzer upgrade

BioResorative’s Chief Scientist named section editor of top-tier Journal of Translational Medicine

Cytel unveiled as alliance partner with OneMedNet

Anebulo announces NIDA grant for investigational treatment of acute cannabis-induced toxicities in children

Clearmind files additional U.S. patent application for MEAI to treat obesity

Alto Neuroscience announces Phase 2b enrollment completion in MDD study

CMS unveils proposed reimbursement for TULSA to treat prostate disease

Rainhouse spotlights CNN reveal on injection cartridge supply issues impacting weight-loss drug shortages

Remembering Elias Vamvakas, a friend and mentor

Exscientia launches AWS AI-powered platform to advance drug discovery

General

More